ERBB2 and breast cancer: Biodistribution studies were performed in NRG mice with s.c. HER2-overexpressing 164/8-1B/H2N.luc + human BC xenografts coinjected intravenously (i.v.; tail vein) with 7–8 MBq (20 μg) of [111In]In-DOTA-trastuzumab mixed with DOTA-trastuzumab (18.5 μg) and 4 kBq (1.5 μg) of [225Ac]Ac-DOTA-trastuzumab (total mass = 40 μg).